+91-8668442535

Global Bacterial Conjunctivitis Market By Drug Class (Fluoroquinolones, Aminoglycosides, Macrolides and Others) - Growth, Future Prospects & Competitive Analysis, 2017- 2025

The drivers responsible for the deep market penetration of drugs utilized for the treatment of bacterial conjunctivitis are the rising prevalence of bacterial conjunctivitis, water and air pollution, and a lack of personal hygiene. Technological advancements in drug development, such as ISV-405 (Azithromycin 2.0%), have resulted in immediate relief because the dose required is minimal, and thus fewer drug-related adverse events. A strong limitation of bacterial conjunctivitis is that the number of parameters that can be detected is very limited, and the overlap of symptoms between adenoviral and bacterial conjunctivitis is ambiguous, resulting in an ineffective dosage regimen.

For the purpose of this study, the various products studied include fluoroquinolones, aminoglycosides, macrolides, and others. The fluoroquinolones are classified as Ciprofloxacin, Ofloxacin, Levofloxacin, Moxifloxacin, Gatifloxacin, and Besifloxacin. Aminoglycosides are further classified as Tobramycin and Gentamycin. Macrolides are divided into two types: erythromycin and azithromycin. Others consist of phenols, glycolipopeptides, and cyclic polypeptides. Market size estimates and forecasts for these segments are provided in US$ Mn, along with the respective CAGRs for the period 2017-2025, using 2016 as the base year.

The geographic segmentation of the global bacterial conjunctivitis market is performed for the regions of North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. 

Market size estimates and forecasts for these segments are provided in US$ Mn, along with the respective CAGRs for the period 2017-2025, using 2016 as the base year.

This report also includes qualitative assessment factors such as market dynamics (drivers, restraints, and opportunities) to have a good understanding of the current and anticipated trends in the global bacterial conjunctivitis market. Market attractiveness assessment and competitive landscape analysis by key players are also presented in the study. Furthermore, this report concludes with a profile of key market players currently enjoying prominent positions in the global bacterial conjunctivitis market. The major players in the bacterial conjunctivitis market are Actavis Plc., Akorn, Inc., Bayer AG, F. Hoffman La-Roche Ltd., InSite Vision Incorporated, Merck & Co., Inc., Novartis AG, Perrigo Company Plc., Pfizer, Inc., and Santen Pharmaceutical Co., Ltd.

Based on drug class, the global bacterial conjunctivitis market is categorized into:

  • Fluoroquinolones
    • Ciprofloxacin
    • Ofloxacin
    • Levofloxacin
    • Moxifloxacin
    • Gatifloxacin
    • Besifloxacin
  • Aminoglycosides
    • Tobramycin
    • Gentamycin
  • Macrolides
    • Erythromycin
    • Azithromycin
  • Others (phenols, glycolipopetides, cyclic polypeptides)

The bacterial conjunctivitis market is driven by factors such as pharmaceutical R&D focusing on the treatment of bacterial conjunctivitis, rising public awareness, and alliances between pharmaceutical giants and research institutes. Furthermore, the increasing prevalence of bacterial conjunctivitis, as well as increased air and water pollution, have an impact on the conjunctiva of the eye. In 2016, the fluoroquinolones segment held the largest market share, chiefly due to factors such as the broad spectrum antimicrobial activity offered by fluoroquinolones against gram-positive, gram-negative, and anaerobic organisms. Because of advances in drug formulation technology, current-generation fluoroquinolones such as gatifloxacin, moxifloxacin, and besifloxacin are now the first line of treatment. The impending patent expiration of blockbuster-branded fluoroquinolone drugs is one of this segment's limitations throughout the forecast period. Aminoglycosides and macrolides together will be the fastest-growing segment throughout the forecast period of 2017–2025. Factors contributing to the growth of this segment are increasing incidences of antibiotic-related drug resistance in bacterial conjunctivitis patients and technological advancement with effective clinical trials conducted to analyze safety and efficacy related to the drug formulation of antibiotics at different concentrations, resulting in immediate relief due to a faster onset of action. The major players in the bacterial conjunctivitis market are Actavis Plc., Akorn, Inc., Bayer AG, F. Hoffman La-Roche Ltd., InSite Vision Incorporated, Merck & Co., Inc., Novartis AG, Perrigo Company Plc., Pfizer, Inc., and Santen Pharmaceutical Co., Ltd.

For the purpose of this study, the global bacterial conjunctivitis market is categorized into the following regional and country-specific markets:

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • rest of Latin America
  • Middle East and Africa
    • GCC
    • Rest of the Middle East and Africa

In the base year 2016, North America was observed to be the largest market for bacterial conjunctivitis. According to the National Eye Institute, in 2016, about 3 million cases of bacterial conjunctivitis were reported. The dominance of North America is mainly attributed to the presence of key drivers, such as the rising prevalence of bacterial conjunctivitis, the existence of developed research and healthcare institutions, and an affordable reimbursement scenario. The market growth in Europe is mainly attributed to the rising prevalence of air and water pollution and the presence of pharmaceutical giants pioneering the treatment of bacterial conjunctivitis. Asia Pacific was observed as the fastest-growing regional segment throughout the forecast period of 2017–2025. Factors that are anticipated to propel market growth are increasing disposable income and a supportive regulatory environment for bacterial conjunctivitis products. Moreover, factors such as developing health infrastructure and business expansion by pharmaceutical giants in untapped markets with unmet medical needs are going to fuel the rapid growth of the bacterial conjunctivitis market in Latin America, the Middle East, and Africa in the near future.

Frequently Asked Questions:

The market for Bacterial Conjunctivitis is expected to reach US$ 436.7 Mn in 2025.

The Bacterial Conjunctivitis market is expected to see significant CAGR growth over the coming years,at 0.54%.

The report is forecasted from 2017-2025.

The base year of this report is 2016.

Actavis Plc.,Akorn, Inc.,Bayer AG,F.Hoffman La-Roche Ltd.,InSite Vision Incorporated are some of the major players in the global market.

Choose License Type
Trusted By
Godaddy
Published Date:  Oct 2017
Category:  Pharmaceuticals
Report ID:   58751
Report Format:   PDF
Pages:   120
Rating:    4.8 (80)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support